Skip to main content

Table 2 Top 40 combinations present in the 1,945 recorded CSCIs

From: Identification of drug combinations administered by continuous subcutaneous infusion that require analysis for compatibility and stability

Drug Combination

Frequency

Drug 1

Drug 2

Drug 3

Drug 4

Morphine

Midazolam

-

-

124a

Oxycodone

Midazolam

-

-

81a

Oxycodone

Levomepromazine

Midazolam

-

60

Morphine

Metoclopramide

-

-

57

Diamorphine

Midazolam

-

-

55a

Morphine

Levomepromazine

Midazolam

-

53

Oxycodone

Haloperidol

Midazolam

-

52

Oxycodone

Haloperidol

-

-

49a

Morphine

Haloperidol

Midazolam

-

46

Alfentanil

Haloperidol

-

-

36

Oxycodone

Levomepromazine

-

-

35a

Alfentanil

Midazolam

-

-

35

Alfentanil

Levomepromazine

Midazolam

-

34

Morphine

Haloperidol

-

-

29

Oxycodone

Metoclopramide

-

-

29a

Oxycodone

Haloperidol

Hyoscine butylbromide

-

29a

Morphine

Cyclizine

-

-

28

Morphine

Levomepromazine

-

-

22a

Alfentanil

Haloperidol

Midazolam

-

22a

Diamorphine

Metoclopramide

-

-

21a

Alfentanil

Metoclopramide

-

-

21

Alfentanil

Hyoscine butylbromide

Levomepromazine

-

20

Oxycodone

Metoclopramide

Midazolam

-

20

Diamorphine

Cyclizine

-

-

19a

Diamorphine

Haloperidol

Midazolam

-

19

Oxycodone

Hyoscine butylbromide

Midazolam

-

18

Alfentanil

Hyoscine butylbromide

Levomepromazine

Midazolam

18

Alfentanil

Metoclopramide

Midazolam

-

17

Morphine

Hyoscine butylbromide

Midazolam

-

17

Diamorphine

Levomepromazine

-

-

17a

Diamorphine

Levomepromazine

Midazolam

-

17

Morphine

Haloperidol

Hyoscine butylbromide

-

17

Morphine

Metoclopramide

Midazolam

-

16

Morphine

Glycopyrronium

Midazolam

-

15

Alfentanil

Cyclizine

-

-

14

Oxycodone

Haloperidol

Hyoscine butylbromide

-

14

Diamorphine

Haloperidol

-

-

14a

Morphine

Hyoscine butylbromide

-

-

13

Dexamethasone

Ketamine

-

-

13

Diamorphine

Cyclizine

Midazolam

-

13

  1. a combinations identified as being analysed at clinically relevant doses for compatibility and stability [10–21]; note that all analysed combinations were reported as compatible under stated conditions